Reducing azithromycin to eliminate trachoma
Azithromycin Reduction to Reach Elimination of Trachoma
This study is testing if stopping or continuing yearly doses of azithromycin can help get rid of trachoma in communities in Niger that have low rates of the disease.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100000 (estimated) |
| Ages | 1 Month and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (Niamey) |
| Trial ID | NCT04185402 on ClinicalTrials.gov |
What this trial studies
This study investigates whether discontinuing or continuing annual mass distribution of azithromycin in communities with low prevalence of trachoma can effectively eliminate the disease. Communities in Maradi, Niger, with up to 20% prevalence of Trachomatous Inflammation - Follicular will be randomly assigned to either continue or stop receiving azithromycin after five years of treatment. The goal is to determine the most effective approach to control and potentially eliminate trachoma in these areas.
Who should consider this trial
Good fit: Ideal candidates are residents of the selected communities in Niger with up to 20% prevalence of Trachomatous Inflammation - Follicular.
Not a fit: Patients living outside the selected communities or those who do not consent to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective strategies for eliminating trachoma in affected communities.
How similar studies have performed: Other studies have shown success with mass azithromycin distribution for trachoma control, making this approach promising yet still requiring further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of appropriate informed consent * Stated willingness to comply with all study procedures * Live in one of the 80 communities with up to 20% prevalence of TF selected for the trial Exclusion Criteria: * Does not consent to participation * Unwilling to comply with all study procedures * Does not live in one of the 80 communities with up to 20% prevalence of TF selected for the trial
Where this trial is running
Niamey
- Programme National de Santé Oculaire (PNSO) — Niamey, Niger (Recruiting)
Study contacts
- Principal investigator: Catherine Oldenburg, ScD, MPH — University of California, San Francisco
- Study coordinator: Catherine Oldenburg, ScD, MPH
- Email: catherine.oldenburg@ucsf.edu
- Phone: (415) 502-8843
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.